In the past decade, one of the major advances in the management of patients with
symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents …

Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …

Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than
20,000 people annually in the United States. There has been a veritable revolution in this …

Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose
chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory …

Over the last two decades, the utilization of various novel therapies in the upfront or salvage
settings has continued to improve survival outcomes for patients with Multiple Myeloma …

The treatment of multiple myeloma has evolved significantly over the past few decades with
the development of novel therapeutics. The introduction of proteasome inhibitors …

Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past
decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered …

Objectives This paper reviews current and emerging therapies for multiple myeloma (MM).
Methods Narrative review. Results MM is a complex, heterogenous condition, and in recent …

An estimated 22 350 patients had multiple myeloma diagnosed in 2013, representing 1.3%
of all new cancers; 10 710 deaths are projected, representing 1.8% of cancer deaths …

Autologous stem cell transplantation (ASCT) has been the mainstay of multiple myeloma
(MM) treatment for approximately 30 years. Although the continuous introduction of novel …